AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93Â US$
arrow_upward
+0,96%(+0,53) 1K
13-noy, 16:00:01 (GMT-5) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoAXGN tikeri uchun statistika yaratilmoqda...
Ochish
55,88Â US$
Yuqori
57,46Â US$
Past
55,01Â US$
Bozor kapitali
3,34Â mlrd
Oʻrtacha hajm
1,98Â mln
Hajmi
1,38Â mln
52 haftalik eng yuqori
59,72Â US$
52 haftalik eng past
23,00Â US$
Aksiya boʻyicha daromad
-0,68Â US$
Beta
1,21
Muomaladagi aksiyalar
59,73Â mln
Xodimlar soni
622
Ochish
55,88Â US$
Yuqori
57,46Â US$
Past
55,01Â US$
Bozor kapitali
3,34Â mlrd
Oʻrtacha hajm
1,98Â mln
Hajmi
1,38Â mln
52 haftalik eng yuqori
59,72Â US$
52 haftalik eng past
23,00Â US$
Aksiya boʻyicha daromad
-0,68Â US$
Beta
1,21
Muomaladagi aksiyalar
59,73Â mln
Xodimlar soni
622
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Zacks
·
2 kun oldin
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Investing.com
·
3 kun oldin
AxoGen at Canaccord forum: growth plan widens beyond nerve repair
Profil
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
AxoGen, Inc Common Stock haqida
CEO-
Xodimlar soni622
Asos solingan2002
Bosh ofislarAlachua, Florida, Amerika Qo‘shma Shtatlari
SektorHealth Care
Soha-
Veb-saytaxogeninc.com